-455G/A β-fibrinogen gene polymorphism, factor V Leiden, prothrombin G20210A mutation and MTHFR C677T, and placental vascular complications

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 2, 2004, Pages 139-147

  Camilleri, Raymond S ^a,b   Peebles, Donald ^a   Portmann, Carol ^a   Everington, Tamara ^b   Cohen, Hannah ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

455G A polymorphism; Fibrinogen; Hereditary thrombophilic markers; Obstetric complications; Placenta

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; FIBRINOGEN; FIBRINOGEN B BETA CHAIN; PROTHROMBIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CAUCASIAN; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; PARITY; PLACENTA CIRCULATION; PREGNANCY COMPLICATION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; THROMBOPHILIA; VASCULAR DISEASE;

3' UNTRANSLATED REGIONS; ABRUPTIO PLACENTAE; ADOLESCENT; ADULT; ALLELES; AMINO ACID SUBSTITUTION; DNA MUTATIONAL ANALYSIS; ETHNIC GROUPS; FACTOR V; FEMALE; FETAL DEATH; FETAL GROWTH RETARDATION; FIBRINOGEN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION, MISSENSE; PLACENTAL CIRCULATION; POINT MUTATION; POLYMORPHISM, GENETIC; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREVALENCE; PROTHROMBIN; THROMBOPHILIA;

EID: 1642341597     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200403000-00005     Document Type: Article

References (67)

1. Ray JG, Laskin CA. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review. Placenta 1999; 20:519-529.
2. Roberts JM. Preeclampsia: what we know and what we do not know. Semin Perinatol 2000; 24:24-28.
3. Lee AJ, Lowe GD, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J 1993; 69:338-342.
4. Bolibar I, Kienast J, Thompson SG, Matthias R, Niessner H, Fechtrup C. Relation of fibrinogen to presence and severity of coronary artery disease is independent of other coexisting heart disease. The ECAT Angina Pectoris Study Group. Am Heart J 1993; 125:1601-1605.
5. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14:54-59.
6. Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U. Fibrinogen is a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group. Arterioscler Thromb Vasc Biol 1996; 16:351-356.
7. Rosengren A, Wilhelmsen L. Fibrinogen, coronary heart disease and mortality from all causes in smokers and non-smokers. The study of men born in 1933. J Intern Med 1996; 239:499-507.
8. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477-1482.
9. Montalescot G, Collet JP, Choussat R, Thomas D. Fibrinogen as a risk factor for coronary heart disease. Eur Heart J 1998; 19(suppl H): H11-H17.
10. Woodward M, Lowe GD, Rumley A, Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study. Eur Heart J 1998; 19: 55-62.
11. Eriksson M, Egberg N, Wamala S, Orth-Gomer K, Mittleman MA, Schenck-Gustafsson K. Relationship between plasma fibrinogen and coronary heart disease in women. Arterioscler Thromb Vasc Biol 1999; 19:67-72.
12. Harjai KJ. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med 1999; 131:376-386.
13. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briet E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71:719-722.
14. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81:680-683.
15. Henschen AH. Human fibrinogen - structural variants and functional sites. Thromb Haemost 1993; 70:42-47.
16. Matsuda M, Sugo T, Yoshida N, Terukina S, Yamazumi K, Niwa K, et al. Structure and function of fibrinogen: insights from dysfibrinogens. Thromb Haemost 1999; 82:283-290.
17. Gurewich V, Lipinski B, Hyde E. The effect of the fibrinogen concentration and the leukocyte count on intravascular fibrin deposition from soluble fibrin monomer complexes. Thromb Haemost 1976; 36:605-614.
18. Smith EB. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin Haematol 1986; 15:355-370.
19. Arbustini E, Morbini P, Bello BD, Prati F, Specchia G. From plaque biology to clinical setting. Am Heart J 1999; 138:S55-S60.
20. Lowe GD. Rheological influences on thrombosis. Bailliere's Best Pract Res Clin Haematol 1999; 12:435-449.
21. Reed T, Tracy RP, Fabsitz RR. Minimal genetic influences on plasma fibrinogen level in adult males in the NHLBI twin study. Clin Genet 1994; 45:71-77.
22. Livshits G, Blettner M, Graff E, Hoting I, Schettler G, Brunner D. The Tel Aviv-Heidelberg three-generation offspring study: genetic determinants of plasma fibrinogen [Abstract 445]. Atherosclerosis 1995; 115(suppl):S119.
23. Krobot K, Hense HW, Cremer P, Eberle E, Keil U. Determinants of plasma fibrinogen: relation to body weight, waist-to-hip ratio, smoking, alcohol, age, and sex. Results from the second MONICA Augsburg survey 1989-1990. Arterioscler Thromb 1992; 12:780-788.
24. Fowkes FG, Pell JP, Donnan PT, Housley E, Lowe GD, Riemersma RA, et al. Sex differences in susceptibility to etiologic factors for peripheral atherosclerosis. Importance of plasma fibrinogen and blood viscosity. Arterioscler Thromb 1994; 14:862-868.
25. Lowe GD, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997; 97: 775-784.
26. Woodward M, Lowe GD, Rumley A, Tunstall-Pedoe H, Philippou H, Lane DA, et al. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1997; 97:785-797.
27. Margaglione M, Cappucci G, Colaizzo D, Pirro L, Vecchione G, Grandone E, et al. Fibrinogen plasma levels in an apparently healthy general population - relation to environmental and genetic determinants. Thromb Haemost 1998; 80:805-810.
28. Connelly JB, Cooper JA, Meade TW. Strenuous exercise, plasma fibrinogen, and factor VII activity [published erratum appears in Br Heart J 1992; 68:160]. Br Heart J 1992; 67:351-354.
29. Marino MW, Fuller GM, Elder FF. Chromosomal localization of human and rat A alpha, B beta, and gamma fibrinogen genes by in situ hybridization. Cytogenet Cell Genet 1986; 42:36-41.
30. Chung DW, Harris JE, Davie EW. Nucleotide sequences of the three genes coding for human fibrinogen. In: Liu CY, Chien S (editors): Fibrinogen, thrombosis, coagulation and fibrinolysis. New York: Plenum Press; 1990, pp. 39-48.
31. Roy SN, Mukhopadhyay G, Redman CM. Regulation of fibrinogen assembly. Transfection of Hep G2 cells with Bβ cDNA specifically enhances synthesis of the three component chains of fibrinogen. J Biol Chem 1990; 265:6389-6393.
32. Humphries SE, Cook M, Dubowitz M, Stirling Y, Meade TW. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987; 1:1452-1455.
33. Thomas AE, Green FR, Kelleher CH, Wilkes HC, Brennan PJ, Meade TW, et al. Variation in the promoter region of the beta fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost 1991; 65:487-490.
34. Scarabin PY, Bara L, Ricard S, Poirier O, Cambou JP, Arveiler D, et al. Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM Study. Arterioscler Thromb 1993; 13:886-891.
35. Heinrich J, Funke H, Rust S, Schulte H, Schonfeld R, Kohler E, et al. Impact of polymorphisms in the alpha-and beta-fibrinogen gene on plasma fibrinogen concentrations of coronary heart disease patients. Thromb Res 1995; 77:209-215.
36. Grant PJ, Humphries SE. Genetic determinants of arterial thrombosis. Bailliere's Best Pract Res Clin Haematol 1999; 12:505-532.
37. Humphries SE, Ye S, Talmud P, Bara L, Wilhelmsen L, Tiret L. European Atherosclerosis Research Study: genotype at the fibrinogen locus (G-455-A beta-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe. Evidence for gender-genotype-environment interaction. Arterioscler Thromb Vasc Biol 1995; 15:96-104.
38. Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, et al. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Circulation 1996; 93:440-449.
39. Tybjaerg-Hansen A, Agerholm-Larsen B, Humphries SE, Abildgaard S, Schnohr P, Nordestgaard BG. A common mutation (G-455→A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study. J Clin Invest 1997; 99:3034-3039.
40. Mannucci PM, Mari D, Merati G, Peyvandi F, Tagliabue L, Sacchi E, et al. Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins. A study in centenarians. Arterioscler Thromb Vasc Biol 1997; 17:755-759.
41. Gardemann A, Schwartz O, Haberbosch W, Katz N, Weiss T, Tillmanns H, et al. Positive association of the beta fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. Thromb Haemost 1997; 77:1120-1126.
42. Grandone E, Margaglione M, Colaizzo D, Cappucci G, Paladini D, Martinelli P, et al. Factor V Leiden, C→T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost 1997; 77:1052-1054.
43. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340:9-13.
44. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361:901-908.
45. Kupferminc MJ, Peri H, Zwang E, Yaron Y, Wolman I, Eldor A. High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss. Acta Obstet Gynecol Scand 2000; 79:963-967.
46. De Groot CJ, Bloemenkamp KW, Duvekot EJ, Helmerhorst FM, Bertina RM, Van Der Meer F, et al. Preeclampsia and genetic risk factors for thrombosis: a case-control study. Am J Obstet Gynecol 1999; 181:975-980.
47. O'Shaughnessy KM, Fu B, Ferraro F, Lewis I, Downing S, Morris NH. Factor V Leiden and thermolabile methylenetetrahydrofolate reductase gene variants in an East Anglian preeclampsia cohort. Hypertension 1999; 33:1338-1341.
48. Livingston JC, Barton JR, Park V, Haddad B, Phillips O, Sibai BM. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol 2001; 185: 153-157.
49. Kim YJ, Williamson RA, Murray JC, Andrews J, Pietscher JJ, Peraud PJ, et al. Genetic susceptibility to preeclampsia: roles of cytosineto-thymine substitution at nucleotide 677 of the gene for methylenetetrahydrofolate reductase, 68-base pair insertion at nucleotide 844 of the gene for cystathionine beta-synthase, and factor V Leiden mutation. Am J Obstet Gynecol 2001; 184:1211-1217.
50. Clauss VA. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematol 1957; 17:237-246.
51. Thomas A, Lamlum H, Humphries S, Green F. Linkage disequilibrium across the fibrinogen locus as shown by five genetic polymorphisms, G/A-455 (HaeIII), C/T-148 (HindIII/AluI), T/G+1689 (AvalI), and BclI (beta-fibrinogen) and Taql (alpha-fibrinogen), and their detection by PCR. Hum Mutat 1994; 3:79-81.
52. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67.
53. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-3703.
54. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutation Ala677→Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997; 77:818-821.
55. Lee AJ, Fowkes FG, Lowe GD, Connor JM, Rumley A. Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study. Thromb Haemost 1999; 81:553-560.
56. Green F, Hamsten A, Blomback M, Humphries S. The role of beta-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost 1993; 70:915-920.
57. Brenner B, Kupferminc MJ. Inherited thrombophilia and poor pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2003; 17:427-439.
58. Gris JC, Quere I, Monpeyroux F, Mercier E, Ripart-Neveu S, Tailland ML, et al. Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent - the Nimes Obstetricians and Haematologists Study5 (NOHA5). Thromb Haemost 1999; 81:891-899.
59. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348:913-916.
60. Ananth CV, Smulian JC, Vintzíleos AM. Incidence of placental abruption in relation to cigarette smoking and hypertensive disorders during pregnancy: a meta-analysis of observational studies. Obstet Gynecol 1999; 93:622-628.
61. Mortensen JT, Thulstrup AM, Larsen H, Moller M, Sorensen HT. Smoking, sex of the offspring, and risk of placental abruption, placenta previa, and preeclampsia: a population-based cohort study. Acta Obstet Gynecol Scand 2001; 80:894-898.
62. Wisborg K, Kesmodel U, Henriksen TB, Olsen SF, Secher NJ. Exposure to tobacco smoke in utero and the risk of stillbirth and death in the first year of life. Am J Epidemiol 2001; 154:322-327.
63. Dejmek J, Solansky I, Podrazilova K, Sram RJ. The exposure of non-smoking and smoking mothers to environmental tobacco smoke during different gestational phases and fetal growth. Environ Health Perspect 2002; 110:601-606.
64. Sibai BM. Thrombophilias and adverse outcomes of pregnancy - what should a clinician do? N Engl J Med 1999; 340:50-52.
65. Walker ID, Greaves M, Preston FE. Guideline - investigation and management of heritable thrombophilia. Br J Haematol 2001; 114; 512-528.
66. Riyazi N, Leeda M, de Vries JI, Huijgens PC, van Geijn HP, Dekker GA. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol 1998; 80:49-54.
67. Everington T, Peebles D, Camilleri R, Maguire N, Cohen H. Reduction in stillbirth and IUGR with aspirin +/-low molecular weight heparin treatment in pregnancy [Abstract]. J Thromb Haemost 2003; 1(suppl 1): P0853.